Health Decisions CEO Redefines Adaptive Clinical Research at BIO International Convention

Dr. Michael Rosenberg and panel will discuss ways to combat economic strain by combining adaptive trial design and operations

Durham, NC: April 21, 2009

imgHealth Decisions (www.healthdec.com) announces that CEO Dr. Michael Rosenberg will lead a paneled breakout session May 20 at the BIO International Convention in Atlanta, Ga. Entitled “Adaptive Research in Practice: Key Elements and Implications for Development,” the session discusses ways to extract hidden value from adaptive clinical trials for dramatically reduced timelines and improved financial viability.

According to Dr. Rosenberg, the drug development industry needs to broaden its perception of adaptive research by extending its core principles to every aspect of clinical programs. The session will encourage drug developers to adopt a comprehensive, technology-enabled approach to adaptive research that focuses equally on design and operational components. A panel of experts spanning major clinical research specialties will discuss concrete examples of how such an approach can boost profitability and alleviate the broader financial pressures on the industry.
About the Breakout Session

Michael Rosenberg“Adaptive methods are becoming an increasingly attractive alternative to the antiquated, inefficient research models that are still standard in the industry. Unfortunately, most adaptive strategies currently in use are limited to statistical and trial design issues, ignoring the sizeable value of operational adaptations. Not only does operational flexibility make design adaptations exponentially more effective, but it also corrects the day-to-day inefficiencies that cause large-scale waste and extend timelines by up to 40 percent.”

Michael Rosenberg
President and CEO

Panel Members:
Mike Ford, Director of Data Management at Health Decisions, will discuss the impact of technology-supported adaptations on key operational components, including enrollment and data management.
Judith Quinlan, Vice President of Adaptive Clinical Trials for Cytel (www.cytel.com), will address how adaptive methods affect drug supply.
Jason Connor, Statistical Scientist at Berry Consultants (www.berryconsultants.com), will discuss adaptive statistics and design.
Session Details
Wednesday, May 20 from 4:00 p.m. – 5:30 p.m.
Part of the Clinical Research/Clinical Trials track
To download a PDF of the full Breakout Session schedule with an abstract of Dr. Rosenberg’s presentation, visit http://convention.bio.org/docs/breakout.pdf.
The 2009 BIO Breakout Sessions include more than 150 sessions across 22 targeted tracks, covering important areas in biotechnology business development, research, marketing, trends, best practices, and more. For more information about BIO Sessions and Speakers, visit http://convention.bio.org/attendees/sessions_speakers.

For sales and marketing information, please contact Mike Watson, Director of Business Development, by email at mwatson@healthdec.com or by phone at +1.919.967.1111 x133.

For more information, contact Courtney Cleaves, Marketing Manager at ccleaves@healthdec.com.

Share Button